News & Updates
PharmEnable and Sosei Heptares enter technology collaboration for AI-driven drug discovery against challenging GPCR target
PharmEnable is delighted to announce that we have entered a new partnership with Sosei Heptares. This collaboration will drive a novel drug discovery programme against a challenging G protein-coupled receptor (GPCR) target, which is associated with neurological...
PharmEnable’s CEO named as one of BioBeat’s 30 Movers and Shakers 2020
We are delighted to announce that PharmEnable’s CEO, Dr Hannah Sore, has been named as one of the top 30 women leaders and innovators in the BioBeat’20 report. The Movers and Shakers in BioBusiness 2020 list showcases outstanding innovators in the UK bioscience scene...
We are attending the BIO-Europe Digital event
We are pleased to announce that PharmEnable will be one of the participating companies at BIO-Europe Digital on 26th-29th October 2020. BIO-Europe Digital is a virtual partnering event for the global biotechnology industry. Hosted by the EBD Group, a leading...
Our CEO joins live debate panel this week
Our CEO, Dr Hannah Sore, will be speaking at this week’s #coffeebuddies debate series, in association with One Nucleus. The virtual #coffeebuddies debates are a fringe event to ON Helix and keep the life sciences community connected, engaged, informed and entertained....
Cambridge Spin-out PharmEnable Raises £1.8 million for Drug Discovery Expansion
£1.8m seed financing led by Cambridge Enterprise alongside angel investors and life science investment fundsUsing advanced medicinal chemistry and AI approaches to develop highly complex and specific drug candidate moleculesWill enable in-house drug discovery across a...
KQ Labs Demo Day
We invite you to come see us at the Demo Day of the KQ Labs Accelerator programme on 5th March 2020 at The Wellcome Trust in London. The programme is run by the Francis Crick Institute, and jointly funded by The Wellcome Trust. The event will showcase the data-driven...
PharmEnable appoints new Board Chair
PharmEnable are delighted to announce the appointment of Dr Jane Dancer as Chair of our Board of Directors. She brings with her a wealth of experience in business development and driving company growth. Her previous roles include Chief Business Officer at F-star...
Director of Molecular Informatics and AI
PharmEnable are delighted to announce and welcome Dr David Vidal as our new Director of Technology. Dr Vidal brings with him an impressive background in computational chemistry, with expertise in machine learning/AI. He has a PhD in Organic Chemistry and has over a...
Joining KQ Labs
We are delighted to announce that PharmEnable have been selected to be part of KQ Labs, a prestigious accelerator programme for data-driven healthcare startups funded by Innovate UK and run by the Francis Crick Institute. The Francis Crick Institute is an independent...
